BLFS

Business Context and Reporting Period

Company: BioLife Solutions, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: The Company develops and markets patented hypothermic storage and cryopreservation solutions (HypoThermosol and CryoStor) for cells, tissues, and organs. It also provides contracted R&D and consulting services. The Company is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 19% to $377,112, driven by a 20% increase in product sales ($367,945) due to new and existing customer orders. Licensing revenue declined slightly to $9,167.
• Margin Compression: Gross margin decreased from 50% to 39%. Cost of product sales rose 45% to $230,277, primarily due to higher production costs at the Contract Manufacturing Organization (CMO).
• Increased Operating Expenses: Total operating expenses increased 22% to $880,231. This was largely driven by $166,951 in one-time manufacturing start-up costs as the Company transitions to internal manufacturing. R&D and Sales & Marketing expenses also increased.
• Widening Net Loss: Net loss increased 30% to $839,568, attributed to higher operating costs and increased interest expense ($106,853 vs. $45,418) due to a higher average debt balance.
• Capital Expenditures: Investing cash outflows surged to $258,721 (from $5,653) due to the build-out of a modular clean room for internal manufacturing.

Guidance, Outlook, Risks, and Contingencies

• Going Concern Warning: The Company has an accumulated deficit of approximately $48 million and has been unable to generate sufficient income to meet operating needs. This raises substantial doubt about its ability to continue as a going concern.
• Liquidity Strategy: Operations are funded primarily through Secured Convertible Multi-Draw Term Loan Facilities from related parties (Thomas Girschweiler and Walter Villiger). As of March 31, 2009, the principal balance was $6,463,127, with $2,536,873 remaining available to draw. An additional $500,000 was drawn in May 2009 (subsequent event).
• Manufacturing Transition: The Company expects to begin internal production in the second quarter of 2009 to reduce costs and enhance flexibility.
• Risks: Future operations depend on continued access to the loan facilities. If investors restrict access, the Company may need immediate additional capital, which may not be available or may be dilutive. Other risks include revenue reductions, increased capital expenditures, and adverse litigation outcomes.
• Share-Based Compensation: The Company issued 1,765,000 non-incentive stock options outside of its expired 1998 plan to directors and employees. Unrecognized compensation expense is approximately $204,761.

Investor Verification Checklist

• Debt Covenants and Conversion Terms: Verify the specific terms of the $9 million aggregate loan facility, including the 7% interest rate, maturity dates (Jan 2010), and conversion discounts (85% of financing price) in the event of an equity raise.
• Going Concern Status: Assess the likelihood of the related-party investors continuing to fund operations if the Company fails to achieve positive cash flow or secure external financing.
• Manufacturing Timeline: Confirm the start date of internal production in Q2 2009 and the projected impact on Cost of Goods Sold (COGS) and gross margins.
• Related Party Transactions: Review the extent of reliance on related parties for both debt financing and services (legal fees, consulting fees totaling $45,956 in Q1 2009).
• Inventory Valuation: Note the reduction in inventory from $625,291 to $453,011 and the expensing of $18,000 in obsolete raw materials/expired products in R&D.